Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
These third-party marketers earn commissions from their insurer clients not only upon initial signups but also every time “their” enrollees renew without changing plans.
The agency cited free speech as its reasoning for rescinding the long-standing policy. While in place, the rule barred companies that agreed to settlements with the Securities and Exchange Commission from publicly denying allegations made by regulators.
RadNet Chaiman and CEO Howard Berger, MD, explains why the company has invested tens of millions into DeepHealth to rapidly build up a new business model.
The company made the changes after its manufacturer rebates for insulin were challenged by the Federal Trade Commission. Among other shifts, Optum said 100% of all rebates will be distributed to customers by 2028.
A global tech and pharma supplier that introduced a generic equivalent to GE Healthcare’s Visipaque during the height of the 2022 contrast shortage has begun offering a substitute for Guerbet’s Dotarem.
An AI startup in the neuro-oncology space has received the government’s go-ahead to market software for analyzing certain fast-growing brain tumors on MRI.
The criminal saga of the X-ray business owner who got caught fleecing CMS of $2 million—while grabbing for another $1.7 million or so—has reached its epilogue.
Butterfly Network, Mindray and Philips introduced new point-of-care ultrasound offerings at ACEP 2022, the annual scientific assembly of the American College of Emergency Physicians.
GE Healthcare may ship its deep learning-based image reconstruction software called AIR Recon DL with new 3D capabilities, the company announced Sept. 29.
An experimental Alzheimer’s drug therapy has slowed cognitive and functional decline by 27% versus placebo in a double-blind, randomized study of 1,795 individuals with early signs and symptoms of the disease.